Edition:
India

Akorn Inc (AKRX.OQ)

AKRX.OQ on NASDAQ Stock Exchange Global Select Market

2.89USD
10:22pm IST
Change (% chg)

$-0.09 (-3.02%)
Prev Close
$2.98
Open
$2.99
Day's High
$2.99
Day's Low
$2.86
Volume
178,173
Avg. Vol
726,845
52-wk High
$19.59
52-wk Low
$2.67

About

Akorn Inc. (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two... (more)

Overall

Beta: 1.34
Market Cap(Mil.): $4,101.01
Shares Outstanding(Mil.): 124.92
Dividend: --
Yield (%): --

Financials

  AKRX.OQ Industry Sector
P/E (TTM): 33.22 29.30 32.55
EPS (TTM): 0.99 -- --
ROI: 6.80 14.23 13.83
ROE: 14.90 15.46 15.25

FDA flags concerns at Akorn's Amityville plant, shares slip

Generic drugmaker Akorn Inc said on Thursday the U.S. Food and Drug Administration had raised concerns about its manufacturing plant in Amityville, New York, that included a lack of records on the maintenance and cleaning of equipment.

28 Feb 2019

UPDATE 2-FDA flags concerns at Akorn's Amityville plant, shares slip

Feb 28 Generic drugmaker Akorn Inc said on Thursday the U.S. Food and Drug Administration had raised concerns about its manufacturing plant in Amityville, New York, that included a lack of records on the maintenance and cleaning of equipment.

28 Feb 2019

FDA flags sanitation concerns at Akorn's Amityville plant

Feb 28 Akorn Inc said on Thursday the U.S. Food and Drug Administration issued observations related to inspection of the company's manufacturing facility in Amityville, New York.

28 Feb 2019

Akorn gets FDA warning letter for Illinois plant, shares drop

Akorn Inc said on Wednesday it received a warning letter from the U.S. Food and Drug Administration following an inspection of the company's Decatur, Illinois manufacturing plant last year.

09 Jan 2019

UPDATE 3-Akorn gets FDA warning letter for Illinois plant, shares drop

Jan 9 Akorn Inc said on Wednesday it received a warning letter from the U.S. Food and Drug Administration following an inspection of the company's Decatur, Illinois manufacturing plant last year.

09 Jan 2019

Akorn gets warning letter from the FDA

Jan 9 Akorn Inc said on Wednesday it received a warning letter from the U.S. Food and Drug Administration, after the company's Decatur, Illinois manufacturing facility was inspected by the regulatory authority in April and May, 2018.

09 Jan 2019

Akorn CEO to retire after drugmaker fails to salvage Fresenius merger deal

WILMINGTON, Del Akorn Inc said late on Friday its Chief Executive Officer would retire following the drugmaker's inability to salvage its takeover deal with Germany's Fresenius SE.

08 Dec 2018

Akorn CEO to retire after drugmaker fails to salvage Fresenius merger deal

WILMINGTON, Del Akorn Inc said late on Friday its Chief Executive Officer would retire following the drugmaker's inability to salvage its takeover deal with Germany's Fresenius SE .

08 Dec 2018

Akorn to Delaware justices: Chancery’s MAC opinion is ‘new blueprint for remorseful buyers’

The global pharmaceutical company Fresenius received a rude shock in the summer of 2017 when Akorn, the generic drugmaker Fresenius had agreed to acquire for $4.75 billion, reported its quarterly financial results. The results were terrible – far worse than Fresenius’ gloomiest projection. Fresenius CEO Stephan Sturm considered the Akorn results the biggest personal embarrassment of his career. Within weeks, the company hired Paul Weiss Rifkind Wharton & Garrison to advise it could w

01 Nov 2018

Earnings vs. Estimates